Suppr超能文献

结核相关性匐行性脉络膜炎:需要采用多种抗结核药物和多种免疫抑制剂双重联合的积极治疗来阻止疾病进展。

Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease.

作者信息

Papasavvas Ioannis, Jeannin Bruno, Herbort Carl P

机构信息

Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialized Care (COS) & Clinic Montchoisi, Rue Charles-Monnard 6, 1003, Lausanne, Switzerland.

出版信息

J Ophthalmic Inflamm Infect. 2022 Feb 8;12(1):7. doi: 10.1186/s12348-022-00282-6.

Abstract

BACKGROUND/PURPOSE: Serpiginous-like choroiditis is a rare immune-mediated sub-entity of tubercular uveitis with a usually deleterious outcome. Treatment is still controversial. The purpose in this case series is to indicate that only aggressive treatment comprising multiple anti-tubercular and multiple immunosuppressive agents seems to be able to halt the disease progression.

METHODS

This retrospective case series included patients diagnosed with Interferon Gamma Release Assays (IGRA) -positive serpiginous choroiditis, seen at the Centre for Ophthalmic Specialized Care, Lausanne, Switzerland, treated with combined multiple antitubercular and immunosuppressive agents at presentation and having a sufficient follow-up. Disease history before referral, appraisal of disease, treatment modalities and follow-up were analyzed. Inclusion criteria were positive IGRA patients with serpiginous choroiditis with complete Spectral-Domain Optic coherence tomography (SD-OCT) and angiography images.

RESULTS

From 2001 to 2020, 24 of 1525 new patients (0.26%) were diagnosed as serpiginous choroiditis. 10/24 were related to tuberculosis (positive IGRA and/or hyper-positive Mantoux test), 8/24 were IGRA negative and in 6 there was no information available. 4/10 tuberculosis related serpiginous patients fulfilled the inclusion criteria. Mean age was 39 ± 5.3 years. Snellen best corrected vision acuity (BCVA) at presentation in 3/4 where the macula was preserved was 0.96 ± 0.08. In 3/4 patients, treatment with multiple tuberculostatic therapy combined with multiple immunosuppressive agents, started at presentation or in the initial months after the first consultation, was shown to stop the progression of the disease, with a retained visual acuity of 1.0. One patient with macular involvement and a bilateral visual acuity of hand movements after 11 years of insufficient treatment, improved his visual acuity to 0.25 OD and 0.05 OS and presented a substantial visual field improvement that stabilized once multiple anti-tubercular and immunosuppressive therapy was introduced.

CONCLUSION

IGRA-positive serpiginous choroiditis (serpiginous-like choroiditis) could be halted by combined multiple tuberculostatic and multiple immunosuppressive agents, as seen in our study where 3/4 early treated patients had conserved central function and one late treated patient had recovered a substantial amount of visual field. In all 4 patients this treatment regimen halted the progression of the disease.

摘要

背景/目的:匐行性脉络膜炎样脉络膜炎是结核性葡萄膜炎中一种罕见的免疫介导的亚型,通常预后不良。治疗仍存在争议。本病例系列的目的是表明,只有包括多种抗结核和多种免疫抑制剂的积极治疗似乎才能阻止疾病进展。

方法

本回顾性病例系列纳入了在瑞士洛桑眼科专科护理中心就诊、通过γ-干扰素释放试验(IGRA)诊断为阳性的匐行性脉络膜炎患者,这些患者在就诊时接受了多种抗结核和免疫抑制剂联合治疗且有足够的随访资料。分析了转诊前的疾病史、疾病评估、治疗方式及随访情况。纳入标准为IGRA阳性且患有匐行性脉络膜炎、有完整的光谱域光学相干断层扫描(SD-OCT)和血管造影图像的患者。

结果

2001年至2020年,1525例新患者中有24例(0.26%)被诊断为匐行性脉络膜炎。24例中有10例与结核病相关(IGRA阳性和/或结核菌素试验强阳性),8例IGRA阴性,6例无相关信息。10例与结核病相关的匐行性患者中有4例符合纳入标准。平均年龄为39±5.3岁。4例中3例黄斑未受累,就诊时的最佳矫正视力(BCVA)为0.96±0.08。3例患者在就诊时或首次会诊后的最初几个月开始接受多种抗结核治疗联合多种免疫抑制剂治疗,结果显示疾病进展停止,视力保持在1.0。1例黄斑受累患者在11年治疗不足后双眼视力仅为手动,在开始接受多种抗结核和免疫抑制治疗后,视力提高到右眼0.25、左眼0.05,视野有显著改善且趋于稳定。

结论

如我们的研究所示,多种抗结核和多种免疫抑制剂联合使用可阻止IGRA阳性匐行性脉络膜炎(匐行性脉络膜炎样脉络膜炎)的进展,4例早期治疗的患者中有3例保留了中心视功能,1例晚期治疗的患者视野有显著恢复。在所有4例患者中,该治疗方案均阻止了疾病进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ea/8821770/b558dab8bcd1/12348_2022_282_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验